In a surprise move, Amgen has decided to conclude its immunotherapy collaboration with Advaxis to develop and commercialise the latter’s Phase I asset, ADXS-NEO, a personalised cancer immunotherapy treatment. The news comes as Advaxis discontinued enrolment in a Phase I/II trialin November for the company’s lead asset, axalimogene filolisbac, in combination with AstraZeneca’s Imfinzi (durvalumab), which faced an FDA hold back in March 2018 following a patient death. Other deals terminated in recent months include Merck & Co.’s collaboration with Samsung Bioepis for Lusduna™ (insulin glargine) and Daiichi Sankyo’s vaccine joint venture with GlaxoSmithKline.